Opioid industry presses for settlement as jury forms
CLEVELAND — Lawyers in the first federal opioid trial resumed selecting a jury Thursday even as a push continued to settle the case before arguments begin.
The second day of picking a jury began after U.S. District Judge Dan Polster, for the second day in a row, denied a request from defendants to delay the trial because of reports of a settlement offer.
By late Thursday morning, 24 potential jurors had been qualified, so the sides could start removing jurors from the pool without giving a reason. One complication in selecting a jury is that the pool comes from counties around Cleveland that have been hard hit by the crisis.
Federal data show that from 2006 through 2012, the area received more doses of opioids per person than the national median.
Arguments are scheduled to begin Monday against some of the biggest names in the pharmaceutical industry unless they can strike a deal.
A source familiar with the negotiations described the outlines of a tentative nationwide settlement as worth tens of billions of dollars. The talks involve the distributors AmerisourceBergen, Cardinal Health and McKesson, as well as drug makers Johnson & Johnson and Teva.
Under the proposed terms, which could change, the three distributors would pay a total of $18 billion over 18 years, Johnson & Johnson would chip in $4 billion over time, and Teva would contribute an estimated $15 billion worth of overdose antidotes and treatment drugs.
Another $14 billion would come from distribution of those drugs, based on calculations of how much a distributor could charge for them.
The person spoke on the condition of anonymity because the talks were continuing. Samantha Fisher, a spokeswoman for the Tennessee attorney general’s office, confirmed a $50 billion settlement framework that was first reported by the New York Times.
If a tentative settlement is reached in the days ahead, it would need signoff by the states and local governments that have sued numerous players in the opioid industry. Perhaps the most wellknown of those, OxyContin maker Purdue Pharma, was taken out of the consolidated federal lawsuits after it filed last month for bankruptcy protection.